• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD opens $38.6M medication management manufacturing plant in Mexico

December 2, 2022 By Sean Whooley

BDBD (NYSE:BDX) announced recently that it inaugurated a new $38.6 million manufacturing facility in Tijuana, Mexico.

Government officials from Mexico and the state of Baja California joined in the opening of the medication management plant. BD plans for the facility to produce devices and technologies that improve medication safety within healthcare settings.

According to a news release, the facility spans 15,775 square meters. The company expects to add 500 new jobs there over the next two years.

In the first phase, BD plans to create 75 jobs responsible for manufacturing automated dispensing cabinets that dispense medication to patients. Also, the company intends to export these devices to North America, Europe, Africa and Asia countries.

“Our new facility in Tijuana is BD’s 12th manufacturing plant in Mexico and is a testament to our commitment to Mexico and the strong relationship we’ve built in communities across the country over the past 65 years,” said Julio Duclos, VP and general director of Mexico, the Caribbean and Central America for BD. “The 17,000 BD employees in Mexico are focused on producing high-quality medical devices that are used by health care providers and patients around the world. We look forward to continuing to grow in Mexico.”

BD continues to expand medication facilities

BD said its expansion in Tijuana represents a four-year strategic investment plan. As part of the plan, the company intends to invest $1.2 billion to expand and upgrade technology and production capacity worldwide, including in Mexico. Just over one year ago, the company broke ground on its $200 million pre-filled drug delivery device manufacturing plant in Spain.

Eventually, BD plans to build upon its six existing sites in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS